Skip to main content
. 2020 Dec 16;65(1):e01103-20. doi: 10.1128/AAC.01103-20

FIG 3.

FIG 3

Time- and dose-dependent effects of shCD5 infusion in C. neoformans-infected CD1 mice. (A) Survival percentage over time of CD1 mice infected with C. neoformans (3 × 104 CFU/g, i.n.) and treated (i.v.) with a single 1.25-mg/kg dose of HSA (+6 days, n = 22) or shCD5 (+1 days, n = 7; +3 days, n = 19; +6 days, n = 8) at different time points (days) postinfection. (B) Survival percentage over time of CD1 mice infected with C. neoformans (3 × 104 CFU/g, i.n.) and treated (i.v.) with single-dose HSA (1.25 mg/kg, n = 4) or shCD5 (0.625 mg/kg, n = 6; 1.25 mg/kg, n = 6; 2.5 mg/kg, n = 5) 3 days later. (C) Lung and brain fungal burdens at days 7, 11, and 14 postinfection of CD1 mice with C. neoformans (3 × 104 CFU/g, i.n.) and treated (i.v.) with a single 1.25-mg/kg dose of HSA (n = 5) or shCD5 (n = 5) 3 days later. Statistical differences between groups were analyzed by log-rank (Mantel-Cox) test (A and B) or Mann-Whitney test (C). *, P ≤ 0.05; **, P ≤ 0.01; ****, P ≤ 0.0001.